Effect of pinaverium bromide on jejunal motility and colonic transit time in healthy humans.
Pinaverium bromide is a specific calcium channel blocker used in the treatment of irritable bowel syndrome (IBS) for its spasmolytic activity. The aim of the present study was to evaluate the effect of orally administered pinaverium bromide on jejunal motility and total and segmental colonic transit time in control subjects. Gastrointestinal studies were performed in 10 healthy volunteers (30 +/- 3 years), before and after a treatment phase of 14 days (150 mg/d). Jejunal motility was measured by prolonged manometry (14 h) and colonic transit time by a multiple ingestion, single marker technique. No significant modification of phase III of the migrating motor complexes was demonstrated. On the contrary, a significant (p < 0.01) but weak decrease of the frequency of contraction was found. Unlike previous studies, no decrease of total or segmental colonic transit time was demonstrated.
Bouchoucha
M
M
Service d'Explorations Fonctionnelles, Hôpital-Laennec, Paris, France.
Salles
J P
JP
Fallet
M
M
Frileux
P
P
Cugnenc
P H
PH
Barbier
J P
JP
D000284:Administration, Oral; D000328:Adult; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D003106:Colon / Q000502:physiology*; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007583:Jejunum / Q000502:physiology*; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D009025:Morpholines; D010276:Parasympatholytics; C013199:pinaverium